{"doi":"10.1016/j.jaci.2015.08.023","title":"Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria","abstract":null,"journal":"Journal of Allergy and Clinical Immunology","year":2016,"id":625316,"datarank":0.7962401546101808,"base_score":5.308267697401205,"endowment":5.308267697401205,"self_citation_contribution":0.7962401546101808,"citation_network_contribution":0.0,"self_endowment_contribution":0.7962401546101808,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":201,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1616981,"name":"Marta Ferrer","orcid":null,"position":1,"is_corresponding":false},{"id":233043,"name":"Jonathan A. Bernstein","orcid":"0000-0002-3476-1196","position":2,"is_corresponding":false},{"id":1616984,"name":"Evgeniya Antonova","orcid":null,"position":3,"is_corresponding":false},{"id":1616986,"name":"Benjamin Trzaskoma","orcid":null,"position":4,"is_corresponding":false},{"id":1616989,"name":"Karina Raimundo","orcid":null,"position":5,"is_corresponding":false},{"id":1616991,"name":"Karin Rosén","orcid":null,"position":6,"is_corresponding":false},{"id":1616993,"name":"Theodore A. Omachi","orcid":null,"position":7,"is_corresponding":false},{"id":1616994,"name":"Sam Khalil","orcid":null,"position":8,"is_corresponding":false},{"id":1616995,"name":"James L. Zazzali","orcid":null,"position":9,"is_corresponding":false},{"id":1616979,"name":"Allen Kaplan","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria","abstract":"BACKGROUND: Few data are available that describe response patterns in patients with chronic idiopathic urticaria (CIU)/chronic spontaneous urticaria (CSU) treated with omalizumab. OBJECTIVE: We sought to describe response patterns by using data from the 3 pivotal omalizumab CIU/CSU trials. METHODS: Every 4 weeks, randomized patients received dosing with placebo or 75, 150, or 300 mg of omalizumab (ASTERIA I: n = 318, 24 weeks; ASTERIA II: n = 322, 12 weeks) or placebo or 300 mg of omalizumab (GLACIAL: n = 335, 24 weeks). Response was defined as well-controlled urticaria (weekly Urticaria Activity Score [UAS7] ≤ 6) or complete response (UAS7 = 0). RESULTS: Response rates were dose dependent and highest with 300 mg of omalizumab. Some patients responded early (before week 4). At week 12, a higher proportion of patients treated with 300 mg of omalizumab reported a UAS7 ≤ 6 (26.0% [75 mg of omalizumab], 40.0% [150 mg of omalizumab], 51.9% [300 mg of omalizumab], and 11.3% [placebo] for ASTERIA I; 26.8% [75 mg of omalizumab], 42.7% [150 mg of omalizumab], 65.8% [300 mg of omalizumab], and 19.0% [placebo] for ASTERIA II; and 52.4% [300 mg of omalizumab] and 12.0% [placebo] for GLACIAL) or a UAS7 = 0 (11.7% [75 mg of omalizumab], 15.0% [150 mg of omalizumab], 35.8% [300 mg of omalizumab], and 8.8% [placebo] for ASTERIA I; 15.9% [75 mg of omalizumab], 22.0% [150 mg of omalizumab], 44.3% [300 mg of omalizumab], and 5.1% [placebo] for ASTERIA II; and 33.7% [300 mg of omalizumab] and 4.8% [placebo] for GLACIAL). In patients receiving 300 mg of omalizumab with 24 weeks of treatment, median time to achieve a UAS7 ≤ 6 was 6 weeks (ASTERIA I and GLACIAL) and median time to achieve a UAS7 = 0 was 12 or 13 weeks (ASTERIA I and GLACIAL, respectively). Some patients who achieved well-controlled urticaria or complete response sustained response throughout the treatment period. CONCLUSION: Benefits of omalizumab treatment were evident early (before week 4) in some patients and persisted to week 24. Use of 300 mg of omalizumab demonstrated best results in controlling CIU/CSU symptoms.","is_dataset_classified":null,"base_score":5.308267697401205,"endowment":5.308267697401205,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"26483177","pmcid":null,"openalex_id":"https://openalex.org/W1787157457","authors":[],"funders":[],"total_grants":0,"fwci":15.5424,"citation_percentile":0.99526814,"influential_citations":0,"citation_trend":[{"year":2016,"count":17},{"year":2017,"count":22},{"year":2018,"count":25},{"year":2019,"count":15},{"year":2020,"count":21},{"year":2021,"count":14},{"year":2022,"count":21},{"year":2023,"count":12},{"year":2024,"count":22},{"year":2025,"count":17},{"year":2026,"count":12}],"oa_status":"hybrid","license":"cc-by-nc-nd","oa_locations":[{"url":"http://www.jacionline.org/article/S0091674915012476/pdf","host_type":"journal"},{"url":"http://www.jacionline.org/article/S0091674915012476/pdf","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0091674915012476?httpAccept=text/plain","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0091674915012476?httpAccept=text/xml","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.jaci.2015.08.023","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/26483177","host_type":"repository"},{"url":"https://hdl.handle.net/10171/69920","host_type":"repository"},{"url":"https://dadun.unav.edu/bitstreams/a7f60e41-7d57-44f7-8cec-a693651e4b45/download","host_type":"repository"}],"fields_of_study":["Urticaria and Related Conditions","Coagulation, Bradykinin, Polyphosphates, and Angioedema","Drug-Induced Adverse Reactions","Adult","Anti-Allergic Agents","Chronic Disease","Female","Humans","Male","Middle Aged","Omalizumab","Risk Factors","Time Factors","Treatment Outcome","Urticaria"],"mesh_terms":["Omalizumab","Adult","Chronic Disease","Female","Humans","Male","Middle Aged","Risk Factors","Time Factors","Urticaria","Treatment Outcome","Anti-Allergic Agents"],"keywords":["Omalizumab","Placebo","Medicine","Dosing","Gastroenterology","Internal medicine","Immunoglobulin E","Antibody","Immunology","Pathology","chronic idiopathic urticaria","chronic spontaneous urticaria","complete response","responder analysis","well-controlled urticaria"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-04T06:25:24.003341Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}